Extending Age Ranges in Breast Cancer Screening in Four European Countries: Model Estimations of Harm-to-Benefit Ratios
Authors:
- Nadine ZielonkeNZNadine Zielonke
- Amarens GeuzingeAGAmarens Geuzinge
- Eveline A. M. HeijnsdijkEHEveline A. M. Heijnsdijk
- Sirpa HeinävaaraSHSirpa Heinävaara
- Carlo SenoreCSCarlo Senore
- Katja JarmKJKatja Jarm
- Harry J. de KoningHKHarry J. de Koning
- Nicolien T. van RavesteynNRNicolien T. van Ravesteyn
- on behalf of the EU-TOPIA ConsortiumOCon behalf of the EU-TOPIA Consortium
Open Access
Abstract
The main benefit of breast cancer (BC) screening is a reduction in mortality from BC. However, screening also causes harms such as overdiagnosis and false-positive results. The balance between benefits and harms varies by age. This study aims to assess how harm-to-benefit ratios of BC screening vary by age in the Netherlands, Finland, Italy and Slovenia. Using microsimulation models, we simulated biennial screening with 100% attendance at varying ages for cohorts of women followed over a lifetime. The number of overdiagnoses, false-positive diagnoses, BC deaths averted and life-years gained (LYG) were calculated per 1000 women. We compared four strategies (50–69, 45–69, 45–74 and 50–74) by calculating four harm-to-benefit ratios, respectively. Compared to the reference strategy 50–69, screening women at 45–74 or 50–74 years would be less beneficial in any of the four countries than screening women at 45–69, which would result in relatively fewer overdiagnoses per death averted or LYG. At the same time, false-positive results per death averted would increase substantially. Adapting the age range of BC screening is an option to improve harm-to-benefit ratios in all four countries. Prioritization of considered harms and benefits affects the interpretation of results.Keywords
Funding Information
- Horizon 2020 Framework Programme (634753)
This publication has 26 references indexed in Scilit:
- Effectiveness of Breast Cancer Screening: Systematic Review and Meta-analysis to Update the 2009 U.S. Preventive Services Task Force RecommendationAnnals of Internal Medicine, 2016
- Evaluation of health benefits and harms of the breast cancer screening programme in the Basque Country using discrete event simulationBMC Cancer, 2015
- Breast-Cancer Screening — Viewpoint of the IARC Working GroupNew England Journal of Medicine, 2015
- Cost‐effectiveness of digital mammography screening before the age of 50 in The NetherlandsInternational Journal of Cancer, 2015
- Consequences of False-Positive Screening MammogramsJAMA Internal Medicine, 2014
- The benefits and harms of breast cancer screening: an independent reviewBritish Journal of Cancer, 2013
- Swedish Two-County Trial: Impact of Mammographic Screening on Breast Cancer Mortality during 3 DecadesRadiology, 2011
- Interpreting Overdiagnosis Estimates in Population-based Mammography ScreeningEpidemiologic Reviews, 2011
- Are benefits and harms in mammography screening given equal attention in scientific articles? A cross-sectional studyBMC Medicine, 2007
- Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial.BMJ, 1988